Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer

Purpose: The effectiveness of poly (adenosine diphosphate–ribose) polymerase (PARP) inhibitor olaparib for metastatic castration-resistant prostate cancer (MCRPC) with multiple loss-of-function alterations in genes that are involved in DNA repair has been demonstrated. We aimed to evaluate the cost-...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Dan, Wu, Bin, Shi, Lizheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870786/
https://www.ncbi.nlm.nih.gov/pubmed/33574757
http://dx.doi.org/10.3389/fphar.2020.610601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870786/
https://www.ncbi.nlm.nih.gov/pubmed/33574757
http://dx.doi.org/10.3389/fphar.2020.610601

Ejemplares similares